EffectiveHigh Impact
Texas Chapter 1003 governs adult stem cell use and investigational stem cell treatments
Texas Health and Safety Code Chapter 1003 establishes state requirements for adult stem cell use in health care and investigational stem cell treatments for certain patients.
Operator impact: Texas regenerative clinics should distinguish adult stem cell use, clinical trials, investigational treatment access, hospital or outpatient setting requirements, IRB oversight, informed consent, and FDA compliance before selling stem-cell programs.
EffectiveMedium Impact
FTC Regenerative Medical Group case remains a warning for amniotic stem-cell therapy claims
FTC case materials state the agency mailed refunds to consumers who paid for allegedly deceptively advertised amniotic stem cell therapy.
Operator impact: Clinics selling amniotic, placental, orthobiologic, or stem-cell-labeled treatments should review claim substantiation, consumer refund exposure, testimonials, sales consultations, and whether marketing overstates pain or orthopedic outcomes.
EffectiveHigh Impact
FDA warns Blue Horizon over umbilical cord blood stem cell and WJ-MSC exosome products
FDA issued a warning letter to Blue Horizon International over marketing stem cell therapy derived from umbilical cord blood and exosome therapy derived from Wharton's Jelly mesenchymal stem cells for allogeneic use.
Operator impact: Regenerative clinics should review whether websites, consult scripts, webinars, provider decks, or patient brochures imply FDA approval, disease-treatment efficacy, or lawful commercial access for stem cell or exosome products without a BLA, IND, or other defensible pathway.
EffectiveHigh Impact
FDA warns on serious risks from unapproved human cell and tissue products
FDA warned patients and consumers about potential serious risks from unapproved products derived from human cells or tissues marketed for treatment or cure of diseases or conditions.
Operator impact: Regenerative, exosome, stem cell, Wharton's jelly, amniotic, or orthobiologic clinics should audit product status, claims, consent language, adverse-event workflows, and FDA enforcement exposure.
EffectiveMedium Impact
FDA approved cellular and gene therapy list clarifies approved-vs-unapproved regenerative products
FDA maintains a list of licensed cellular and gene therapy products, creating an important reference point for distinguishing FDA-approved regenerative products from cash-pay products marketed without approval.
Operator impact: Clinics should train intake, sales, and provider teams not to conflate FDA-registered facilities, clinical research, tissue-bank accreditation, or supplier claims with FDA product approval.
WatchHigh Impact
Florida Stem Cell Therapy Workgroup remains a state regulatory watch item
Florida Board of Medicine scheduled a Stem Cell Therapy Workgroup meeting on April 9, 2026 with agenda, public book, and meeting audio materials.
Operator impact: Florida regenerative clinics should monitor workgroup materials for emerging rulemaking, board interpretation, disciplinary posture, consent standards, product-source expectations, and advertising boundaries under the 2025 stem cell law.
EffectiveHigh Impact
FDA warns Dynamic Stem Cell Therapy over umbilical-cord derived product
FDA issued a warning letter to Dynamic Stem Cell Therapy after reviewing marketing for an umbilical cord-derived stem cell product for allogeneic use.
Operator impact: Clinics marketing umbilical-cord derived stem cell therapy should review disease claims, structure/function claims, patient outcome claims, FDA-approval statements, and whether therapies are being sold outside approved clinical investigation or licensure pathways.
EffectiveHigh Impact
FDA warns New Life Medical Services over umbilical cord, amniotic fluid, and exosome products
FDA warning letter to New Life Medical Services cited human products derived from umbilical cord, amniotic fluid, and exosomes, including Rexo and Rexo Charge.
Operator impact: Clinics should verify that regenerative product vendors can support claims around homologous use, minimal manipulation, allogeneic use, donor screening, labeling, adverse events, and lawful distribution before buying or administering products.
EffectiveHigh Impact
FDA warns Platinum Biologics over Nano PRP Jelly, Nano Flex, NanoEx, and Nano Xsomes
FDA warning letter to Platinum Biologics cited umbilical cord-derived products and exosome products marketed for allogeneic use, including Nano PRP Jelly, Nano Flex, NanoEx, and Nano Xsomes.
Operator impact: Clinics using branded regenerative inventory should review whether product names such as PRP-style, jelly, flex, nano, or exosome language obscure that the product may be regulated as an unapproved new drug or unlicensed biological product.
EffectiveHigh Impact
FDA warns Innate Healthcare Institute over UC-MSC therapy claims
FDA warning letter to Innate Healthcare Institute cited marketing of umbilical cord mesenchymal stem cells and UC-MSC therapy for allogeneic use.
Operator impact: Clinics marketing immune modulation, autoimmune, inflammation, tissue regeneration, or chronic disease claims around UC-MSCs should review whether claims imply unapproved drug or biologic use.
EffectiveMedium Impact
California chiropractic accusation highlights stem-cell therapy scope and notice risk
California Board of Chiropractic Examiners accusation materials referenced stem cell therapy definitions, HCT/Ps, and regenerative treatment-related compliance issues.
Operator impact: Chiropractic-med spa hybrids, regenerative referral shops, and wellness clinics should review scope-of-practice, medical director relationships, ownership/control, patient notices, and whether non-physician providers are participating in regenerative medicine beyond their authority.
EffectiveHigh Impact
Florida authorizes certain physician-performed non-FDA-approved stem cell therapies
Florida law allows allopathic and osteopathic physicians to perform certain non-FDA-approved stem cell therapies related to orthopedics, wound care, or pain management when statutory conditions are met.
Operator impact: Florida clinics should review the law narrowly: it does not create a blanket permission slip for med spas, NPs, chiropractors, exosomes, amniotic fluid, growth factors, Wharton's Jelly claims, or broad disease-treatment marketing outside the statute.
EffectiveHigh Impact
FDA warns Supreme Rejuvenation over stem cell exosome products
FDA warning letter to Supreme Rejuvenation cited human umbilical cord mesenchymal stem cell-derived exosome products and stem cell exosome gels marketed through websites and Instagram.
Operator impact: Med spas and aesthetic-regenerative clinics should review exosome gels, post-laser exosome add-ons, microneedling exosome upsells, Instagram claims, and whether cosmetic positioning crosses into drug or biologic claims.
EffectiveHigh Impact
FDA warns Chara Biologics over CharaExo and umbilical cord products
FDA warning letter to Chara Biologics cited a human amniotic fluid product, exosome protocols, and human umbilical cord-derived products marketed or distributed for a wide range of diseases and conditions.
Operator impact: Regenerative clinics should audit starter packages, provider training programs, disease-protocol PDFs, sample dosing guides, referral materials, and continuing education-style content because FDA may treat those materials as evidence of intended use.
EffectiveHigh Impact
FTC stem cell enforcement remains a warning signal for regenerative clinics
FTC announced court orders banning Stem Cell Institute co-founders and related companies from marketing stem cell treatments and requiring more than $5.1 million in payments.
Operator impact: Clinics using regenerative-medicine claims should expect scrutiny around efficacy, FDA approval implications, disease-treatment claims, testimonials, and sales presentations to vulnerable patients.
EffectiveHigh Impact
FDA warns Evolutionary Biologics over EXO RNA, EVO JEL, and EVO HYBRID
FDA warning letter to Evolutionary Biologics cited EXO RNA, EVO JEL, and EVO HYBRID, including exosome, umbilical cord, placental tissue, and amniotic membrane-derived products.
Operator impact: Clinics should review whether flowable umbilical cord, placental, amniotic, exosome, or hybrid regenerative products are being treated like simple office inventory despite FDA concerns over minimal manipulation and non-homologous use.
EffectiveHigh Impact
Ninth Circuit reinforces FDA authority over California SVF stem-cell procedures
The Ninth Circuit reversed the lower court in United States v. California Stem Cell Treatment Center and held that the clinic's SVF product was subject to FDA regulation.
Operator impact: Autologous adipose-derived stem cell, SVF, same-day procedure, and practice-of-medicine defenses should be legal-reviewed before any clinic builds offers, sales scripts, or informed-consent language around them.
EffectiveHigh Impact
FDA warns Neobiosis over amniotic fluid and Wharton's Jelly products
FDA warning letter to Neobiosis cited amniotic fluid, Wharton's Jelly cellular, and Wharton's Jelly acellular products sold to physicians, medical centers, pain clinics, and wellness centers.
Operator impact: Pain clinics, wellness clinics, and orthobiologics practices should review whether supplier materials, public interviews, Facebook posts, YouTube videos, and educational content create intended-use evidence for unapproved regenerative products.
EffectiveHigh Impact
Washington AG complaint against US Stemology flags deceptive stem-cell marketing risk
Washington Attorney General complaint against US Stemology alleged deceptive stem-cell marketing and referenced Washington's statutory notice requirements for non-FDA-approved stem cell therapies.
Operator impact: Regenerative clinics should review testimonials, disease-cure claims, seminar funnels, lead magnets, consult scripts, and patient urgency tactics under both medical-board and consumer-protection risk lenses.
EffectiveHigh Impact
Eleventh Circuit confirms FDA authority over Florida SVF stem-cell procedure
The Eleventh Circuit affirmed that U.S. Stem Cell Clinic's SVF procedure did not fall within the same surgical procedure exception or the 361 HCT/P exception.
Operator impact: Florida and Southeast regenerative clinics should not assume same-day autologous processing, fat-derived cell isolation, or in-office procedure framing avoids FDA drug and biologic regulation.
EffectiveHigh Impact
FDA public safety notification flags serious adverse events from unapproved exosome products
FDA issued a public safety notification after reports of serious adverse events in patients treated with unapproved products marketed as containing exosomes.
Operator impact: Clinics offering exosome add-ons for aesthetics, orthopedics, wound care, sexual health, hair restoration, or systemic disease claims should treat adverse-event risk, source verification, consent language, and emergency protocols as front-line business controls.
EffectiveHigh Impact
DOJ permanent injunction bars U.S. Stem Cell Clinic from SVF products absent FDA approval
A federal court entered a permanent injunction barring U.S. Stem Cell Clinic and related defendants from selling or providing SVF products absent FDA approval.
Operator impact: Regenerative operators should treat injunction history as a clear warning that repeated SVF or unapproved stem-cell commercialization can escalate from warning letters to federal litigation and shutdown-level relief.
EffectiveMedium Impact
FDA notified R3 Stem Cell affiliates over unapproved stem-cell products
FDA announced it put R3 Stem Cell on notice and notified more than 50 affiliate centers or clinics that R3 products were not approved by FDA.
Operator impact: Affiliate clinic models should review whether central brand claims, supplier marketing, provider locator pages, co-branded pages, and franchise-style materials create enforcement risk for every downstream clinic using the product.
EffectiveHigh Impact
Washington requires notice and signed consent for non-FDA-approved stem cell therapy
Washington RCW 18.130.420 requires license holders performing non-FDA-approved stem cell therapy to provide written notice and obtain signed informed consent before performing the therapy.
Operator impact: Washington regenerative clinics should operationalize statutory notices, entrance signage, patient-copy workflows, signed consent forms, FDA-approval status disclosures, and exemptions for approved IND/BLA or accredited institutional settings.
WatchMedium Impact
FSMB regenerative and stem cell therapy recommendations remain a state-board benchmark
FSMB's regenerative and stem cell therapy report recommends state-board oversight around promotion, communication, informed consent, and physician practices involving stem cell and regenerative therapies.
Operator impact: Clinics should treat FSMB guidance as a likely state-board benchmark for evaluating clinical rationale, evidence claims, specialty competence, patient disclosures, advertising, and complaint investigations.
